Alvarez Secord A et al. Final analysis of the single-arm phase II PICCOLO trial of mirvetuximab soravtansine-gynx (MIRV) in folate receptor alpha (FRα)-positive, third-line and later (3L+), recurrent platinum-sensitive ovarian cancer (PSOC). ESMO Gynecological Cancers Congress 2025;Abstract 76MO.
Coleman RL et al. Efficacy of third-line and later (3L+) therapies post poly (ADP-ribose) polymerase inhibitor (PARPi) exposure in recurrent platinum-sensitive ovarian cancer (PSOC): A pooled clinical trial database analysis. ASCO 2025;Abstract 5579.
Colombo R et al. The journey of antibody-drug conjugates: Lessons learned from 40 years of development. Cancer Discov 2024;14(11):2089-108. Abstract
Dum D et al. Patterns of trophoblast cell surface antigen 2 (TROP2) and epithelial cell adhesion molecule (EPCAM) expression in human tumors: A tissue microarray study on 14,766 tumors. ESMO 2022;Abstract 83P.
Lee D et al. HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers. ESMO 2024;Abstract 765P.
Lee EK et al. (ENCORE) Rinatabart sesutecan for patients with advanced ovarian cancer: Results from dose expansion cohort B1 of phase I/II study. SGO 2025;Abstract.
Lee EK et al. A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer. ESMO 2024;Abstract 719MO.
Makker V et al. Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 1 final analysis. ESMO 2025;Abstract 957P.
Martin LP et al. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol 2017;147(2):402-7. Abstract
Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract
Moore KN et al. Raludotatug deruxtecan (R-DXd) monotherapy in patients (pts) with heavily pretreated platinum-sensitive ovarian cancer (PSOC): Subgroup analysis of a phase I study. ESMO Gynecological Cancers Congress 2025;Abstract 77MO.
Moore KN et al. Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study. SGO 2024;Abstract LBA04.
Moore KN et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023;389(23):2162-74. Abstract
Moore KN et al. Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study. ESMO 2023;Abstract 745MO.
Oaknin A et al. First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer. ESMO 2025;Abstract 1065MO.
Oaknin A et al. Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase 2 TROPION-PanTumor03 study. ESMO 2024;Abstract 714MO.
Petersen ME et al. Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates. Mol Cancer Ther 2024;23(5):606-18. Abstract
Rao Q et al. JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies. ESMO 2024;Abstract 759P.
Ray-Coquard IL et al. Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01. ESMO 2025;Abstract LBA42.
Ray-Coquard IL et al. Results from the first-in-human phase I study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha in recurrent platinum resistant high-grade serous ovarian cancer (HGSOC). ESMO 2025;Abstract 1067P.
Schram A et al. Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation. SGO 2024;Abstract LBA26.
Shu J et al. IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study. ESMO 2024;Abstract 720MO.
Swain SM et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022;106:102378. Abstract
Tarantino P, Tolaney SM. Detecting and managing T-DXd-related interstitial lung disease: The five “S” rules. JCO Oncol Pract 2023;19(8):526-7. Abstract
Tew WP et al. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol 2022;40(33):3878-81. Abstract
Wang D et al. Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study. ESMO 2024;Abstract 715MO.